Skip to main content
Fig. 6 | Cancer Nanotechnology

Fig. 6

From: Delivery of melittin-loaded niosomes for breast cancer treatment: an in vitro and in vivo evaluation of anti-cancer effect

Fig. 6

IC50 value in study groups after 48- and 72-h treatment with melittin and melittin-loaded niosome (P < 0.001 ***) on 4T1 cell line (a). IC50 value in study groups after 48- and 72-h treatment with melittin, and melittin-loaded niosome (P < 0.001 ***) on SKBR3 cell line (b). IC50 value in study groups after 48- and 72-h treatment with melittin, and melittin-loaded niosome on 4T1 cells with each other (P < 0.001 ***) (c). IC50 value in study groups after 48- and 72-h treatment with melittin, and melittin-loaded niosome on SKBR3 cells with each other (P < 0.001 ***) (d). Data are shown as mean ± SEM. The mean values with different superscript letters are significantly different (P ≤ 0.05)

Back to article page